What Hypervision Surgical does
Hypervision Surgical develops AI-powered hyperspectral imaging technology for intraoperative guidance, using safe light-based optical imaging to characterise tissue in real time and help identify tumours, healthy tissue, nerves and blood vessels without contrast agents. The company, a spin-out from King's College London's Institute for Healthcare Engineering, is initially focused on neurosurgery and holds ISO 13485, UKCA marking and FDA 510(k) clearance. It was founded in 2020 by Michael Ebner (CEO), Tom Vercauteren, Sébastien Ourselin and Jonathan Shapey, and is based in London.
Hypervision Surgical is a healthcare tool on Falcoscan. AI hyperspectral imaging that helps surgeons see tissue in real time. Falcoscan rates Hypervision Surgical with an Opportunity score of 84/100, a Saturation score of 11/100, and a Wrapper-risk score of 9/100. Market signal: rising. Hypervision Surgical is founded in 2020, currently at Series_a stage. Pricing: Paid.